NFE2L2 and acute lymphoblastic leukemia: Our enhanced understanding of NRF2 biology in T-ALL may allow us to propose targeted therapeutic approaches, which could be used in combination with standard chemotherapy in order to improve the outcome of relapsed/refractory T-ALL patients.